News
Merck expects $200M tariff hit amid Gardasil fallout
The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 billion analysts had predicted. Adjusted earnings of $2.22 per share outpaced expectations of $2.13 a share.
Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...
Several major drugmakers are counting on their manufacturing flexibility to counter potential disruptions from tariffs ...
Merck & Co (MRK) and Procter & Gamble (PG) are lower despite beating earnings expectations after lowering their guidance ...
With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
Julie Hyman provides an overview of the top stories of the trading day in just 60 seconds on Yahoo Finance's Market Minute. Merck & Company (MRK) warns investors that it expects a $200 million hit ...
Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback